Dupilumab Treatment Reduces Total IgE Levels in Patients 6 Months and Older with Moderate-to-Severe Atopic Dermatitis

被引：0
|
作者：
Siegfried, Elaine [1 ]
Cork, Michael [2 ]
Boguniewicz, Mark [3 ]
Deleuran, Mette [4 ]
Simpson, Eric [5 ]
Chen, Zhen [6 ]
Clearfield, Drew [6 ]
Shah, Parul [7 ]
Rodriguez-Marco, Ainara [8 ]
机构：
[1] St Louis Univ, St Louis, MO USA
[2] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England
[3] Natl Jewish Hlth, Denver, CO USA
[4] Aarhus Univ Hosp, Aarhus, Denmark
[5] Oregon Hlth & Sci Univ, Portland, OR USA
[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[7] Regeneron, Tarrytown, NY USA
[8] Sanofi, Paris, France
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2023年 / 151卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
456
引用
收藏
页码：AB149 / AB149
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Eichenfield, L. F.
    Blauvelt, A.
    Rosmarin, D.
    Hussain, I.
    Davis, J. D.
    Li, M.
    Zhang, Q.
    Gadkari, A.
    Eckert, L.
    Kamal, M. A.
    Bansal, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S104 - S104
  • [32] Efficacy and tolerance of dupilumab in patients with moderate-to-severe atopic dermatitis and obesity
    Dupuis, Josephine
    Tauber, Marie
    Mahe, Emmanuel
    Jachiet, Marie
    Soria, Angele
    Tetart, Florence
    Puzenat, Eve
    Pasteur, Justine
    Raison-Peyron, Nadia
    Giordano-Labadie, Francoise
    Droitcourt, Catherine
    Leleu, Camille
    Nosbaum, Audrey
    Aubert, Helene
    Moigne, Marie L. E.
    Bernier, Claire
    Barbarot, Sebastien
    Ezzedine, Khaled
    Diaz, Emmanuelle
    Hubiche, Thomas
    Faiz, Sarah
    Azib, Selma
    Dezoteux, Frederic
    Chosidow, Olivier
    Staumont-Salle, Delphine
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025, 39 (02) : e174 - e178
  • [33] Dupilumab treatment in children with moderate-to-severe atopic dermatitis increases levels of bone mineralization biomarkers
    Irvine, A. D.
    Paller, A.
    Horowitz, J. E.
    Farrell, A.
    Hatsell, S.
    Ehmann, P.
    Rodriguez Marco, A.
    Tian, T.
    Cyr, S. L.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S110 - S110
  • [34] Dupilumab treatment in children with moderate-to-severe atopic dermatitis increases levels of bone mineralization biomarkers
    Irvine, Alan D.
    Paller, Amy S.
    Horowitz, Julie E.
    Farrell, Annamaria
    Hatsell, Sarah
    Ehmann, Peter
    McDonald, Robert
    Marco, Ainara Rodriguez
    Tian, Tingting
    Cyr, Sonya L.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [35] Dupilumab Reduces Biomarkers Indicative of Type 2 Inflammation in Children Aged ≥ 6 Months to < 6 YearsWith Moderate-to-Severe Atopic Dermatitis
    Pinter, Andreas
    Paller, Amy
    Guttman-Yassky, Emma
    Boguniewicz, Mark
    Sun, Yiping
    Wolfe, Kelley
    Dillon, Myles
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 100 - 100
  • [36] Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis
    Paller, A.
    Guttman-Yassky, E.
    Boguniewicz, M.
    Sun, Y.
    Wolfe, K.
    Dillon, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S51 - S51
  • [37] DUPILUMAB REDUCES BIOMARKERS INDICATIVE OF TYPE 2 INFLAMMATION IN CHILDREN AGED 6 MONTHS TO 5 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Paller, Amy S.
    Flohr, Carsten
    Guttman-Yassky, Emma
    Boguniewicz, Mark
    Wipperman, Matthew F.
    Rodriguez Marco, Ainara
    Wolfe, Kelley
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 30 - 31
  • [38] Tear fluid dupilumab levels of patients with moderate-to-severe atopic dermatitis and ocular surface disease
    Achten, R.
    Thijs, J.
    van Luijk, C.
    van Wijk, F.
    van Luin, M.
    El Amrani, M.
    Delemarre, E.
    de Graaf, M.
    Bakker, D.
    de Boer, J.
    de Bruin-Weller, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S196 - S196
  • [39] Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to 5 years with moderate-to-severe atopic dermatitis
    Paller, A.
    Guttman-Yassky, E.
    Boguniewicz, M.
    Levit, N.
    Wolfe, K.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S250 - S250
  • [40] Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers
    Paller, Amy S.
    Simpson, Eric L.
    Siegfried, Elaine C.
    Cork, Michael J.
    Wollenberg, Andreas
    Arkwright, Peter D.
    Praestgaard, Amy
    Prescilla, Randy
    Wang, Zhixiao
    Marco, Ainara Rodriguez
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB40 - AB40
12345